Solving COVID: June 2, 2021
Life-long immunity, a breakthrough on blood clots, and more

- 1. Where things stand
- 2. Studies suggest COVID-19 immunity could last 'possibly a lifetime'
- 3. Scientist believes he's found solution to rare blood clots linked to vaccines
- 4. Moderna says its COVID-19 vaccine is 100 percent effective in adolescents
- 5. Dogs are better than tests for detecting COVID-19, researchers say
A free daily digest of the biggest news stories of the day - and the best features from our website
Thank you for signing up to TheWeek. You will receive a verification email shortly.
There was a problem. Please refresh the page and try again.
1. Where things stand
The U.S. hit an encouraging new milestone this week, recording a daily average of 17,248 new coronavirus cases. This is the first time that number has been lower than 20,000 since the beginning of the COVID-19 pandemic. According to The New York Times, "no state is seeing a major increase in cases," and some states have seen their caseloads plummet by half in just two weeks. Sixty-three percent of Americans over the age of 12 have received at least one dose of a vaccine, creeping closer to President Biden's goal of vaccinating 70 percent of the adult population by July 4. Still, experts are worried about new variants spreading rapidly in other parts of the world, and call for widespread vaccination campaigns in vulnerable countries. "If world leaders don't act now, the end of the COVID pandemic may come with a horrible form of herd immunity, as more transmissible variants that are taking hold around the world kill millions," writes Zeynep Tufekci at the Times.
2. Studies suggest COVID-19 immunity could last 'possibly a lifetime'
Two new studies suggest COVID-19 immunity following infection could last a year, or "possibly a lifetime, improving over time especially following vaccination," The New York Times reported, hopefully allaying "lingering fears that protection against the virus will be short-lived." When taken together, the studies suggest most (but not all) vaccinated individuals who were previously infected with COVID-19 "will not need boosters," wrote the Times. Those who were vaccinated without having previously contracted the virus will likely need the extra dose. Experts expect immunity in these individuals to "play out very differently," as "immune memory" may look different following vaccination compared to natural infection. The results also underscore the idea that previous infection is not enough to protect individuals long-term on its own — even those who have recovered should be vaccinated, wrote the Times.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
3. Scientist believes he's found solution to rare blood clots linked to vaccines
Rolf Marschalek, a professor at Goethe University in Frankfurt, Germany, claims he's identified the cause of rare blood clots linked to the COVID-19 vaccines developed by Johnson & Johnson and the University of Oxford and AstraZeneca. He also believes he's found a way for the producers to modify their shots so the clots no longer occur, the Financial Times reports. Marschalek said his research zeroed in on the vaccines' adenovirus vectors, which "send the spike protein into the cell nucleus rather than the cytosol fluid inside the cell where the virus normally produces proteins." The theory is that once the spike protein enters the nucleus, some parts splice and create mutant versions, FT reports. Hypothetically, those mutant proteins are then "secreted by cells into the body" where they may trigger potentially fatal blood clots. The research, Marschalek argues, suggests the vaccine developers could "modify the sequence of the spike protein" so that it doesn't split apart.
4. Moderna says its COVID-19 vaccine is 100 percent effective in adolescents
Moderna's COVID-19 vaccine was found in a study to be 100 percent effective in adolescents between the ages of 12 and 17, and the company is set to seek FDA approval for this age group. Moderna said that in the phase 2/3 study that enrolled more than 3,700 participants, there were no COVID-19 cases reported among the group that received two doses of its vaccine, per CNBC. The vaccine was "generally well tolerated," and "no significant safety concerns have been identified to date," the company also said. "We are encouraged that mRNA-1273 was highly effective at preventing COVID-19 in adolescents," Moderna CEO Stéphane Bancel said. "It is particularly exciting to see that the Moderna COVID-19 vaccine can prevent SARS-CoV-2 infection." Moderna said it's planning to submit data to the FDA to seek authorization for adolescents in early June.
5. Dogs are better than tests for detecting COVID-19, researchers say
Dogs are being trained to detect COVID-19 in Thailand, France, Britain, Chile, Australia, Belgium, Germany, and other countries, and preliminary studies "suggest that their detection rate may surpass that of the rapid antigen testing often used in airports and other public places," The New York Times reports. Cells infected with COVID-19 have a specific scent that dogs can sniff out in seconds, even if an infected person doesn't have symptoms. Six labradors being trained at Bangkok's Chulalongkorn University accurately detect the COVID-19 virus 96.2 percent of the time in controlled settings, university researchers say, and studies have found results almost that impressive in Germany and the United Arab Emirates. The researchers hope that dogs can be deployed at transportation hubs, stadiums, and other crowded public places to find people infected with COVID-19, or used to sniff out clusters of cases in cities and other communities. Proponents say dogs are not only more accurate at detecting COVID-19, they are also much faster and cheaper than polymerase chain reaction (PCR) testing.
Continue reading for free
We hope you're enjoying The Week's refreshingly open-minded journalism.
Subscribed to The Week? Register your account with the same email as your subscription.
Sign up to our 10 Things You Need to Know Today newsletter
A free daily digest of the biggest news stories of the day - and the best features from our website
-
Elix, part of Mar-Bella Collection review: a Greek beachside oasis
The Week Recommends This family-friendly resort offers access to a beautiful beach
By Kaye O'Doherty Published
-
The Indigenous referendum splitting the Australian public
The Explainer The referendum would form a federal body of Aboriginal people in Australia
By Justin Klawans Published
-
Who is Laphonza Butler, California's new senator and champion of labor?
Why Everyone's Talking About Butler has served as the president of pro-choice advocacy group EMILY's List
By Justin Klawans Published
-
How do we calculate mass deaths?
The Explainer Recent revisions to 9/11, Libyan flood and Covid-19 death tolls raise questions over estimates
By Harriet Marsden, The Week UK Published
-
You can now get a new Covid booster shot. Should you?
Unless you are old or otherwise at high risk, it isn't a 'slam dunk'
By Peter Weber Published
-
Is it time to mask up again?
Today's Big Question A rise in Covid-19 cases brings back the possibility of mask mandates
By Joel Mathis Published
-
The NHS plan for virtual wards to beat winter crisis
feature Patients with respiratory infections to be given wearable devices that allow doctors to monitor them at home
By The Week Staff Published
-
Understanding the new Covid-19 variant, Eris
Speed Read The formally named EG.5 is making the rounds, but we don't have to worry just yet
By Devika Rao Published
-
The new Covid variant Eris behind a rise in cases this summer
feature Concerns over ’flying blind’ as routine testing is no longer freely available and less data is being collected
By Felicity Capon Published
-
The new push to solve long Covid
Speed Read Patients say researchers have been too slow to address the condition
By Joel Mathis Published
-
The deadly rise of fungal spores
feature Climate change is increasing the world’s susceptibility to fungal pathogens
By The Week Staff Published